Identification of Steroid Esters in Cattle Hair at Ultra-Trace Levels
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2. -
Quick Determination of 105 Doping in Animal Derived Food By
QTRAP®质谱系统对动物源食品中105种兴奋剂的快速分析 检测 Quick Determination of 105 Doping in Animal – derived Food by QTRAP® System 杨总1,陈丹2,程海燕1,李立军1,郭立海1 Yang Zong1,Chen Dan2,Cheng Haiyan1,Li Lijun1,Guo Lihai1 1 SCIEX亚太应用支持中心,上海; 2 湖北省武汉食品化妆品检验所 1 SCIEX Asia Pacific Application Support Center, Shanghai, China; 2 Wuhan Institute for Food and Cosmetic Control, Hubei Province, China; Keywords:doping;SCIEX QTRAP® 4500 系统; LC-MS/ MS;quantitative analysis 引言 在现代畜牧养殖业中,一些不法分子长期使用各种饲料添加 剂和人工合成激素类化合物,造成动物源食品中的药物残留,最 终成为食源性兴奋剂的来源[1]。运动员食用含有某些药物残留的食 物,可导致其兴奋剂检测呈阳性。国家反兴奋剂中心和世界反兴 奋剂机构(WADA)等组织机构明确规定了兴奋剂的违禁药物的种 SCIEX ExionLC™液相和SCIEX QTRAP® 4500质谱系统 类,主要包含了β-受体激动剂、固醇类激素、糖皮质激素、利尿 剂、玉米赤霉醇类等等。总体而言,兴奋剂的作用主要是对身体或 者中枢神经系统起到选择性的作用,能促进肌肉组织快速增长、增 4. 建立好了105种兴奋剂EPI二级谱库,软件自动进行匹配二级质 强机体活力和敏捷度,还可使运动员疲劳减轻,自信心增强,注意 谱图,保证筛查结果准确可靠; 力集中[2]。因此在体育赛事过程中,为了保证赛事结果的公平、公 正,在运动员食品安全保障过程中,必须对食品中兴奋剂进行严格 5. 方法现成,省去开发方法的时间,提高了工作效率; 的监控。本文针对动物源食品中的常见105种兴奋剂,建立了采用 QTRAP®系统快速筛查和定量方法,该方法完全满足在体育赛事过 1. 实验方法 程中对兴奋剂监管的分析要求。 1.1 液相色谱条件 该方案的特点和优势 色谱柱:Phenomenex Kinetex 2.6µm F5 100 Å 150×3 µm 流动相:水相(水中含有5 mM乙酸铵和0.01%甲酸),有机 1. 方法覆盖面广,包含了常见五大类β-受体激动剂、固醇类激 相为乙腈,梯度洗脱 素、糖皮质激素、利尿剂、玉米赤霉醇类兴奋剂,共105种; 1.2 质谱条件 2. 本实验详细优化了前处理过程,考察了化合物的稳定性; 扫描模式:MRM-IDA-EPI,正负离子同时扫描,MRM离子对见 3. 实验采用MRM-IDA-EPI扫描实现一针进样同时定量和定性分 表1。 析,快速灵敏,满足国内外标准品的要求; RUO-MKT-02-9756-ZH-A p 1 离子源:ESI源;离子源参数:喷雾电压(IS):5500V(+) 2. 结果与讨论 /-4500V(-);离子源温度:600℃;气帘气(CUR):35psi;碰 2.1 前处理过程的优化 撞气(CAD):Medium;雾化气(GS1):55psi;辅助雾化气 (GS2):60psi 本实验详细优化了前处理过程,实验结果表明在动物源食品 中酸化乙腈的提取效率最高,绝大部分化合物回收率在70%以上 1.3 样品前处理过程 (见图1、图2、图3)。由于基质的复杂性,实验比较了5种不同 称取5g样品于50 mL离心管 → 加入10 mL乙酸铵缓冲溶液混 的SPE柱的净化效率,由图4可以看出,PRIME HLB 净化效果最优 异,回收率较高。 匀 → 加入β-葡萄糖醛甙酶进行酶解 → 加入酸化乙腈进行提取, 震荡混匀后加入NaCl和Mg2SO4 → 萃取之后高速离心取上清液采用 PRIME HLB进行净化 → 吹干后复溶上机测试。 100 80 60 40 20 0 酸化叔丁基甲醚 酸化乙腈 碱化乙腈 图1. -
MMC International BV
M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange -
(12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub
US 2008 OO63698A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub. Date: Mar. 13, 2008 (54) CRYSTALLIZATION INHIBITION OF DRUGS now abandoned, which is a continuation of applica IN TRANSIDERMAL DRUG DELIVERY tion No. 10/010,342, filed on Dec. 5, 2001, now SYSTEMIS AND METHODS OF USE abandoned. (75) Inventor: Rod Lawson Hartwig, Plantation, FL (60) Provisional application No. 60/251.294, filed on Dec. (US) 5, 2000. Correspondence Address: Publication Classification Noven Pharmaceuticals, Inc. Jay G. Kolman, Esq. (51) Int. Cl. 11960 S.W. 144 Street A6II 3/56 (2006.01) A6F 3/00 (2006.01) Miami, FL 33186 (US) A6IP 43/00 (2006.01) (73) Assignee: NOVEN PHARMACEUTICALS, A6F 3/02 (2006.01) INC. (52) U.S. Cl. ........................... 424/448; 424/449; 514/170 (57) ABSTRACT Appl. No.: 11/897,189 (21) The invention relates to compositions and methods for (22) Filed: Aug. 29, 2007 making a transdermal drug delivery system capable of achieving substantially zero-order kinetics for delivery of Related U.S. Application Data the active agent over a period of time in excess of 24 hours and at least 72 hours, comprising a pharmaceutically accept (63) Continuation of application No. 10/751,152, filed on able active agent carrier and a rosin ester which provides a Jan. 2, 2004, now abandoned, which is a continuation crystal inhibiting and drug stabilizing effect on the active of application No. 10/353,624, filed on Jan. 29, 2003, agents incorporated therein. 13 2 2 Patent Application Publication Mar. -
Potential of Guggulsterone, a Farnesoid X Receptor Antagonist, In
Exploration of Targeted Anti-tumor Therapy Open Access Review Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer Sosmitha Girisa , Dey Parama , Choudhary Harsha , Kishore Banik , Ajaikumar B. Kunnumakkara* Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India *Correspondence: Ajaikumar B. Kunnumakkara, Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India. [email protected]; [email protected] Academic Editor: Gautam Sethi, National University of Singapore, Singapore Received: August 8, 2020 Accepted: September 14, 2020 Published: October 30, 2020 Cite this article: Girisa S, Parama D, Harsha C, Banik K, Kunnumakkara AB. Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer. Explor Target Antitumor Ther. 2020;1:313-42. https://doi.org/10.37349/ etat.2020.00019 Abstract Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains a serious concern due to the limitations associated with currently available cancer management strategies. Therefore, alternative strategies are highly required to overcome these glitches. The importance of medicinal plants as primary healthcare has been well-known from time immemorial against various human diseases, including cancer. Commiphora wightii that belongs to Burseraceae family is one such plant which has been used to cure various ailments in traditional systems of medicine. -
Nandrolone Decanoate Enhances Hypothalamic Biogenic Amines in Rats
Nandrolone Decanoate Enhances Hypothalamic Biogenic Amines in Rats 1 1 2 2 TETSURO TAMAKI , TAKEMASA SHIRAISHI , HIROSHI TAKEDA , TERUHIKO MATSUMIYA , 3 3,4 ROLAND R. ROY , and V. REGGIE EDGERTON 1Department of Physiology, Division of Human Structure and Function, and 2Department of Pharmacology, Tokyo Medical College, Tokyo, JAPAN; and 3Brain Research Institute and 4Department of Physiological Science, University of California, Los Angeles, CA ABSTRACT TAMAKI, T., T. SHIRAISHI, H. TAKEDA, T. MATSUMIYA, R. R. ROY, and V. R. EDGERTON. Nandrolone Decanoate Enhances Hypothalamic Biogenic Amines in Rats. Med. Sci. Sports Exerc., Vol. 35, No. 1, pp. 32–38, 2003. Purpose: To identify possible mechanisms for an anabolic-androgenic steroid induced increase in aggressive behavior and work capacity, the levels of some biogenic amines considered to be closely related to a systemic hyper-adrenergic state were measured in selected regions of the brain. Methods: Wistar male rats were divided randomly into five groups: nontreated (control), oil-vehicle-treated (vehicle) or one of three (therapeutic dose and 10- or 100-fold higher dose) anabolic-androgenic steroid-treated (steroid-1, -2, -3) groups. Rats in the steroid and vehicle groups were given a single dose of nandrolone decanoate or oil vehicle, respectively, one week before tissue sampling. The levels of norepinephrine (NE) and its metabolite, 4-hydroxy-3-methoxyphenylglycol (MHPG), serotonin (5-HT) and its metabolite, 5-hydroxy- indole-3-acetic acid (5-HIAA) were measured in the cerebral cortex, hypothalamus and cerebellum by high-performance liquid chromatography. Immunostaining for c-fos was performed as a confirmation of increased neural activity. Results: The levels of NE and MHPG were increased by ~2- and ~7-fold in the hypothalamus of the steroid-2 compared with the control and vehicle groups. -
Control Be Implemented. the First Large-Scale Systematic Olympic Games
Br J Sports Med: first published as 10.1136/bjsm.11.4.162 on 1 December 1977. Downloaded from 162 Brit. J. Sports Med. - Vol. 1 1, No. 4, December 1977, pp. 162-169 RADIOIMMUNOASSAY OF ANABOLIC STEROIDS: AN EVALUATION OF THREE ANTISERA FOR THE DETECTION OF ANABOLIC STEROIDS IN BIOLOGICAL FLUIDS Robert DUGAL, Ph.D., Claire DUPUIS, Ph.D. and Michel J. BERTRAND, Ph.D. Centre de Recherches en Sciences de la Sante, Institut National de la Recherche Scientifique, Centre Hospitalier Louis-H. Lafontaine, Montrdal, Quebec, Canada ABSTRACT Recently developped radioimmunoassays (RIA) for the analysis of anabolic steroids and their metabolites in biological fluids were tested for cross-reactivity with other types of steroids. Results show that the degree of desirable cross-reactivity within the two classes of orally active anabolic steroids vary widely and that the antiserum for 19-Nortestosterone (the active principle of intramuscular, preparations) has a very high degree of undesirable cross- reactivity with components of oral contraceptives. Single and multiple dose studies in human volunteers demonstrate that the detection level and degree of retrospectivity are likewise variable but that the test easily detects most anabolic steroids during treatment. At the present time, the combination of the three antisera for the assay of a sample appears to be a relatively rapid and economic method for screening large numbers of samples in situations where doping control of anabolic steroids is required. The importance of utilizing physico-chemical means for identification of RIA potential positives is emphasized. INTRODUCTION (Sumner, 1974: Brooks et al, 1975) and identification procedures for a limited number of them have also been copyright. -
Nomenclature of Steroids
Pure&App/. Chern.,Vol. 61, No. 10, pp. 1783-1822,1989. Printed in Great Britain. @ 1989 IUPAC INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY and INTERNATIONAL UNION OF BIOCHEMISTRY JOINT COMMISSION ON BIOCHEMICAL NOMENCLATURE* NOMENCLATURE OF STEROIDS (Recommendations 1989) Prepared for publication by G. P. MOSS Queen Mary College, Mile End Road, London El 4NS, UK *Membership of the Commission (JCBN) during 1987-89 is as follows: Chairman: J. F. G. Vliegenthart (Netherlands); Secretary: A. Cornish-Bowden (UK); Members: J. R. Bull (RSA); M. A. Chester (Sweden); C. LiCbecq (Belgium, representing the IUB Committee of Editors of Biochemical Journals); J. Reedijk (Netherlands); P. Venetianer (Hungary); Associate Members: G. P. Moss (UK); J. C. Rigg (Netherlands). Additional contributors to the formulation of these recommendations: Nomenclature Committee of ZUB(NC-ZUB) (those additional to JCBN): H. Bielka (GDR); C. R. Cantor (USA); H. B. F. Dixon (UK); P. Karlson (FRG); K. L. Loening (USA); W. Saenger (FRG); N. Sharon (Israel); E. J. van Lenten (USA); S. F. Velick (USA); E. C. Webb (Australia). Membership of Expert Panel: P. Karlson (FRG, Convener); J. R. Bull (RSA); K. Engel (FRG); J. Fried (USA); H. W. Kircher (USA); K. L. Loening (USA); G. P. Moss (UK); G. Popjiik (USA); M. R. Uskokovic (USA). Correspondence on these recommendations should be addressed to Dr. G. P. Moss at the above address or to any member of the Commission. Republication of this report is permitted without the need for formal IUPAC permission on condition that an acknowledgement, with full reference together with IUPAC copyright symbol (01989 IUPAC), is printed. -
Regioselective Enzymatic Acylation of Vicinal Diols of Steroids
Tetrahedron 61 (2005) 3065–3073 Regioselective enzymatic acylation of vicinal diols of steroids M. Manuel Cruz Silva,a Sergio Rivab and M. Luisa Sa´ e Meloa,* aCentro de Estudos Farmaceˆuticos, Lab. Quı´mica Farmaceˆutica, Faculdade de Farma´cia, Universidade de Coimbra, Rua do Norte 3000-295 Coimbra, Portugal bIstituto di Chimica del Riconoscimento Molecolare, C.N.R., Via Mario Bianco 9, 20131 Milano, Italy Received 28 October 2004; revised 29 November 2004; accepted 25 January 2005 Abstract—Monoacylated derivatives of a complete set of 2,3- and 3,4-vicinal diols of steroids were prepared by regioselective lipase- catalysed transesterification reactions. The enzymes displayed different selectivities towards the vicinal diols depending on the configuration of the hydroxyl groups. q 2005 Elsevier Ltd. All rights reserved. 1. Introduction Studies on the transesterification of polyfunctionalyzed steroids have shown that hydrolases can have access to Polyhydroxylated steroids bearing vicinal diols on the substituents either on the A-ring or on the D-ring and/or on A-ring are frequently found in Nature and some of them the side-chain of steroids. Several lipases showed a have relevant biological activities. For instance, the trans- preference for C-3 hydroxyl groups,13,14 whereas the diaxial 2b,3a-di-hydroxy pattern is present in natural protease subtilisin Carlsberg catalysed the acylation of 14 sulphated sterols with antiviral1 or anti-angiogenic2 action, C-17 OH. Moreover, stereoselective resolutions of while 2a,3a-diols isolated from marine sources hold epimeric alcohols located on the steroid side-chain have 15 cytotoxic activity.3 Steroidal saponins displaying trans- been carried out by lipase PS and, more recently, by 16 diequatorial 2a,3b-vicinal diols are quite frequent as subtilisin. -
The Format of This Leaflet Was Determined by the Ministry of Health and Its Content Was Checked and Approved by It on July 2012
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it on July 2012 1. NAME OF THE MEDICINAL PRODUCT PROGYLUTON Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Calendar-pack containing 11 white tablets of 2 mg estradiol valerate each, plus 10 light brown tablets of 2 mg estradiol valerate and 0.5 mg norgestrel each. 3. PHARMACEUTICAL FORM Coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indication Two phase preparation for climacteric and cycle disturbances. 4.2 Posology and method of administration Proguluton is a cyclic HRT product. One tablet is to be taken orally once a day for 21 days, followed by a 7 day tablet free interval. Therefore each new pack is started after a 28 day cycle. The white tablets should be taken from days 1 to 11 followed by the brown tablets from days 12 to 21. It is recommended that the tablets are taken at the same time every day For initiation and continuation of treatment of peri- and post-menopausal symptoms the lowest effective dose for the shortest duration (see also Section 4.4) should be used. For women still having periods, the first tablet should be taken on the 5th day of their menstrual period. If menstruation has stopped, or is infrequent or sporadic, then the first tablet can be taken any time If the patient is being transferred from a continuous HRT product, the patient may start Progyluton on any convenient day. For those transferring from a cyclic or sequential product, Progylton should be started following completion of the previous regimen If a tablet is missed, it should be taken as soon as possible, unless it is more than 12 hours late. -
Download News 2/2020
Polymere und Fluoreszenz Gleichgewicht der 360°-Trinkwasseranalyse Kräfte Trilogie Fluoreszenzspektroskopie von Basispolymeren aus der Leistung und Robustheit in Automatische, simultane Industrie Einklang mit Empfindlichkeit und schnelle Analyse von und Geschwindigkeit Pestiziden INHALT APPLIKATION »Plug und Play«-Lösung für das Krankheits-Screening – MALDI-8020 zum Screening der Sichelzellen anämie 4 Maßgeschneiderte Software- Lösungen für jede Messung – Makro-Programmierung für Shimadzu UV-Vis und FTIR 8 Auf der sicheren Seite: Steroid - nachweis in Arzneimitteln und Nahrungsergänzungsmitteln mit einem LCMS-8045 11 MSn-Analyse nicht-derivatisier- ter und Mtpp-derivatisierter Peptide – Zwei aktuelle Unter- suchungen zur Anwendung von LC-MS-IT-TOF-Geräten 18 Polymere und Fluoreszenz – Teil 2: Wieviel Fluoreszenz zeigt ein Poly mer für eine Qualitäts - kontrolle? 26 PRODUKTE Gleichgewicht der Kräfte – LCMS-8060NX: Leistung und Robustheit mit Empfindlichkeit, und Geschwindigkeit 7 360°-Trinkwasseranalyse: Episode 2 – Automatische, simul- Enrico Davoli mit dem PESI-MS-System – einem Gerät zu reinen Forschungszwecken (research-use only = RUO) tane und schnelle Analyse von Pestiziden mit Online-SPE und UHPLC-MS/MS 14 Vielseitiges Tool für die Automobil - industrie – Neue HMV-G3 Serie 17 Eine globale Lösung Kopfschmerz ade – Anleitung zur Auswahl der idealen C18-Säule 22 Validierte Methode für monoklo- nale Antikörper-Medikamente – dank globaler Bewertung der nSMOL-Methodik in menschlichem Serum 24 AKTUELLES Zusammenarbeit Eine globale Lösung -
Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems. National Institute for Health and Welfare (THL), Research 30
Sanna Kailanto Sanna Kailanto Interactions of Nandrolone Sanna Kailanto and Psychostimulant Drugs RESEARCH Interactions of Nandrolone and RESEARCH Psychostimulant Drugs on Central on Central Monoaminergic Monoaminergic Systems Systems Monoaminergic Systems Monoaminergic Central on Drugs Psychostimulant and Nandrolone of Interactions This study had four main aims. First, it aimed to explore the effects of nandrolone decanoate on dopaminergic and serotonergic activities in rat brains. Second, it set out to assess whether nandrolone pre-exposure modulates the acute neurochemical and behavioral effects of psychostimulant drugs in experimental animals. A third aim was to investigate if AAS-pretreatment-induced changes in brain reward circuitry are reversible. Finally, the study was also intended to evaluate the role of androgen receptors in nandrolone’s ability to modulate the dopaminergic and serotonergic effects of stimulants. The results of the study show that AAS pretreatment inhibits the reward- related neurochemical and behavioral effects of amphetamine, MDMA and cocaine in experimental animals. Given that LMA, stereotyped behavior and accumbal outflow of DA and 5-HT are all related to reward, this study suggests that nandrolone, at tested doses, significantly affects the rewarding properties of stimulant drugs. Furthermore, it seems that these effects could be long- lasting and that the ability of nandrolone to modulate reward-related effects of stimulants depends on AR or ER activation. .!7BC5<2"HIFILD! National Institute for Health and Welfare P.O. Box 30 (Mannerheimintie 166) FI-00271 Helsinki, Finland Telephone: +358 20 610 6000 30 ISBN 978-952-245-258-0 www.thl.fi 30 2010 30 Sanna Kailanto Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems Academic dissertAtIoN To be presented with the permission of the Faculty of Biological and Environmental Sciences, University of Helsinki, for public examination in the Arppeanum auditorium, Helsinki University Museum, Snellmaninkatu 3, Helsinki, on April 29nd, at 12 o’clock noon.